Want to join the conversation?
$LLY's revenue by product had mixed results YoverY as Forteo, Strattera, Trajenta, and Animal Health revenues increased YoverY while Alimta, Humulin, Cymbalta, Zyprexa, and Evista reported declines in revenue; Evista declined significantly by 35%. On a YoverY basis, Humalog, Cialis, and Effient reported flat revenues compared to last year.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?